Overview

ZD6474(Vandetanib) + Alimta Combo Study

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.
Phase:
Phase 1
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Pemetrexed